Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136805) titled 'A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: VivaVision Biotech, Inc
Condition:
Non-infectious Anterior Uveitis
Intervention:
Drug: VVN461 Ophthalmic Solution 1.0%
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 1, 2025
Target Sample Size: 152
To know more, visit https://clinicaltrials.gov/ct2/show/NCT0713...